Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & amp; lipid profile in early menopausal women
CONCLUSIONS: Continuous long-term therapy with DRSP 2 mg/E2 1 mg significantly lowered 24 h systolic and diastolic BPs and reduced the risk of cardiovascular disease in early menopausal women with stage 1 hypertension. Timely initiated menopausal hormone therapy can have beneficial effects on BP and can reduce the incidence of cardiovascular disease in menopausal women.PMID:35662091 | DOI:10.4103/ijmr.IJMR_478_20 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - June 6, 2022 Category: Biomedical Science Authors: Aleksandar Đogo Branko Do žić Svetlana Vujovi ć Dragana Srebro Ivan Do žić Source Type: research
Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & amp; lipid profile in early menopausal women
CONCLUSIONS: Continuous long-term therapy with DRSP 2 mg/E2 1 mg significantly lowered 24 h systolic and diastolic BPs and reduced the risk of cardiovascular disease in early menopausal women with stage 1 hypertension. Timely initiated menopausal hormone therapy can have beneficial effects on BP and can reduce the incidence of cardiovascular disease in menopausal women.PMID:35662091 | DOI:10.4103/ijmr.IJMR_478_20 (Source: Indian J Med Res)
Source: Indian J Med Res - June 6, 2022 Category: Research Authors: Aleksandar Đogo Branko Do žić Svetlana Vujovi ć Dragana Srebro Ivan Do žić Source Type: research
Systemic hormonal contraception and risk of venous thromboembolism
ConclusionsAn increased risk of venous thromboembolism is associated with ethinylestradiol-containing combined preparations. The use of estradiol-containing combined preparations confers only a slightly increased risk, possibly driven by cyproterone-containing combined oral contraceptives, whereas the use of progestin-only contraception is not associated with venous thromboembolism. (Source: Acta Obstetricia et Gynecologica Scandinavica)
Source: Acta Obstetricia et Gynecologica Scandinavica - May 28, 2022 Category: OBGYN Authors: Oskari Heikinheimo,
Elena Toffol,
Timo Partonen,
Anna But,
Antti Latvala,
Jari Haukka Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat
. (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - May 26, 2022 Category: Endocrinology Authors: Muqing Gu Xiangyan Ruan Yanqiu Li Tianhe Li Chenghong Yin Alfred O. Mueck Source Type: research
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Feb;15(2):121-137. doi: 10.1080/17512433.2022.2054413. Epub 2022 Mar 27.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COV...
Source: Expert Review of Clinical Pharmacology - March 21, 2022 Category: Drugs & Pharmacology Authors: C éline Gérard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Mar 27:1-17. doi: 10.1080/17512433.2022.2054413. Online ahead of print.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COVE...
Source: Expert Review of Clinical Pharmacology - March 21, 2022 Category: Drugs & Pharmacology Authors: C éline Gérard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Mar 21. doi: 10.1080/17512433.2022.2054413. Online ahead of print.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COVERED: ...
Source: Expert Review of Clinical Pharmacology - March 21, 2022 Category: Drugs & Pharmacology Authors: C éline Gerard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Mar 21. doi: 10.1080/17512433.2022.2054413. Online ahead of print.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COVERED: ...
Source: Pharmacological Reviews - March 21, 2022 Category: Drugs & Pharmacology Authors: C éline Gerard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Mar 21. doi: 10.1080/17512433.2022.2054413. Online ahead of print.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COVERED: ...
Source: Expert Review of Clinical Pharmacology - March 21, 2022 Category: Drugs & Pharmacology Authors: C éline Gerard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Mar 21. doi: 10.1080/17512433.2022.2054413. Online ahead of print.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COVERED: ...
Source: Pharmacological Reviews - March 21, 2022 Category: Drugs & Pharmacology Authors: C éline Gerard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research
